Results 101 to 110 of about 15,358 (185)

The Validation and Cross-Cultural Adaptation of the Arabic Version of the Polycystic Ovary Syndrome Quality of Life Scale (PCOSQOL). [PDF]

J Clin Med
Alwatban L, Sayed A, Alwatban R, Alwatban M, Alyousefi N.   +4 more
europepmc   +1 more source

Hirsutism

, 2015
openaire   +2 more sources

A mixed-method analysis of health literacy and indicators of well-being in women with polycystic ovary syndrome across the lifespan. [PDF]

Ther Adv Reprod Health
Douglas CC, Hashmi A, Mclain A, Arentson-Lantz EJ.   +3 more
europepmc   +1 more source

Decreased serum MG53 levels are associated with SHBG and androgen excess in women with polycystic ovary syndrome. [PDF]

Sci Rep
Coşkun ES, Gencer FK, Salman S, Nurlu N, Bacak HB, Kumbasar S, Timur GY, Çelikoğlu E, Ünlü Ş, Tunççağ F, Güven R.   +10 more
europepmc   +1 more source

The Quantification of Terminal Hair by Digital Microscopy: Advancements Towards a More Objective Diagnosis of Hirsutism. [PDF]

Clin Cosmet Investig Dermatol
De Kroon RWPM, Den Heijer M, Haarman SJ, Verdaasdonk RM, Heijboer AC.   +4 more
europepmc   +1 more source

Hormonal risk factors and androgen and glucocorticoid dysregulation in Sjogren's disease and non-Sjogren's sicca. [PDF]

Rheumatology (Oxford)
Turner JD, Tsapparelli J, Gilligan LC, Pucino V, Bandeira M, Baranskaya A, Rauz S, Poveda-Gallego A, Higham J, Richards A, Brown RM, Bowman SJ, Taylor AE, Nayar S, Fisher BA.   +14 more
europepmc   +1 more source

Nonclassic congenital adrenal hyperplasia and bilateral pheochromocytomas in a patient with a germline pathogenic <i>MAX</i> variant. [PDF]

JCEM Case Rep
Parisien-La Salle S, Legault J, Dumas N, Arjane P, Trudel D, Bourdeau I.   +5 more
europepmc   +1 more source

Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycystic ovary syndrome-associated hirsutism: a double-blind, randomised, placebo-controlled trial. [PDF]

EClinicalMedicine
Lobo R, Angulo A, Muñoz A, Colli E, Escobar-Morreale HF, Luque-Ramírez M, Zatik J, Regidor PA.   +7 more
europepmc   +1 more source

Neuropeptide Y Promoter Variant rs16147 (-399 T/C) Is Associated With Susceptibility to Polycystic Ovary Syndrome. [PDF]

Cureus
Yukcu F, Akcilar R, Biyik I, Sisman HI.
europepmc   +1 more source

Beyond Monotherapy: Targeting the Triad of Insulin Resistance, Hyperandrogenism and Obesity in Polycystic Ovary Syndrome. [PDF]

AACE Endocrinol Diabetes
Shaharyar A, Chaudhary S, Jha V, Bhadada SK, Walia R.   +4 more
europepmc   +1 more source